Jon W. Henry

Array ( [id] => 13369103 [patent_doc_number] => 20180236092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => HUMAN INTERFERON-BETA VARIANT CONJUGATED IMMUNOCYTOKINE AND METHOD FOR PREPARING SAME [patent_app_type] => utility [patent_app_number] => 15/693148 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15693148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158867 [patent_doc_number] => 20180030132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR' [patent_app_type] => utility [patent_app_number] => 15/693160 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 40384 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15693160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126301 [patent_doc_number] => 20180009887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'METHODS OF TREATING DISEASES' [patent_app_type] => utility [patent_app_number] => 15/686365 [patent_app_country] => US [patent_app_date] => 2017-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 16796 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15686365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150137 [patent_doc_number] => 20180021401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE AND BACTERIAL INFECTION' [patent_app_type] => utility [patent_app_number] => 15/672903 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 15399 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15672903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715673 [patent_doc_number] => 20190248900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ANTIBODY TO PROGRAMMED CELL DEATH 1 (PD-1) AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/321124 [patent_app_country] => US [patent_app_date] => 2017-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 287 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13687521 [patent_doc_number] => 20170354715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON [patent_app_type] => utility [patent_app_number] => 15/668001 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106853 [patent_doc_number] => 10072059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Targeting of human interferon antagonists [patent_app_type] => utility [patent_app_number] => 15/642989 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 4766 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15642989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023475 [patent_doc_number] => 20190322742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => ANTI-CD19 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/310555 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12000286 [patent_doc_number] => 20170304440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'Treatment Methods for Rheumatoid Arthritis' [patent_app_type] => utility [patent_app_number] => 15/634917 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 28175 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15634917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12305931 [patent_doc_number] => 09938343 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies [patent_app_type] => utility [patent_app_number] => 15/626812 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 8149 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15626812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16734459 [patent_doc_number] => 10960080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Pegylated porcine interferon and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/311540 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 5950 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16311540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689575 [patent_doc_number] => 20170355742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => GM-CSF Variants and Methods of Use [patent_app_type] => utility [patent_app_number] => 15/616216 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378144 [patent_doc_number] => 11236141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Targeted mutant interferon-beta and uses thereof [patent_app_type] => utility [patent_app_number] => 16/301304 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 2 [patent_no_of_words] => 51764 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023670 [patent_doc_number] => 20170313769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'INTERFERON BETA ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/581079 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 35317 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834647 [patent_doc_number] => 20170216367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Treatment of diseases and conditions caused by increased vascular permeability' [patent_app_type] => utility [patent_app_number] => 15/492446 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8821 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15492446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501325 [patent_doc_number] => 20190194317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => HUMANIZED ANTI CLEVER-1 ANTIBODIES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/093257 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277275 [patent_doc_number] => 20190135922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/088802 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -194 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11837866 [patent_doc_number] => 20170219585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS AS A PREDICTOR OF PATIENT RESPONSE TO INTERFERON-A THERAPY' [patent_app_type] => utility [patent_app_number] => 15/485420 [patent_app_country] => US [patent_app_date] => 2017-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 4458 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15485420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756608 [patent_doc_number] => 10975145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event [patent_app_type] => utility [patent_app_number] => 15/483619 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15856 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699873 [patent_doc_number] => 20170360891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon [patent_app_type] => utility [patent_app_number] => 15/467884 [patent_app_country] => US [patent_app_date] => 2017-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15467884 [rel_patent_id] =>[rel_patent_doc_number] =>)